Acquisitions - Schedule of MediFind Purchase Price Consideration (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Jun. 30, 2023 |
Jul. 31, 2024 |
Jul. 31, 2023 |
Jul. 31, 2024 |
Jul. 31, 2023 |
|
| Business Acquisition [Line Items] | |||||
| Equity consideration paid to sellers | $ 0 | $ 4,676 | $ 0 | $ 4,676 | |
| MediFind | |||||
| Business Acquisition [Line Items] | |||||
| Cash consideration paid to sellers | $ 4,104 | $ 4,104 | $ 4,104 | ||
| Equity consideration paid to sellers | 4,676 | ||||
| Liabilities incurred to sellers | 91 | ||||
| Total fair value of acquisition consideration | $ 8,871 | ||||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|